Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
Evidence from well-designed clinical trials is key to promote greater acceptance and access to palliative care
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
However, the future of TKI combinations for these rare tumours is uncertain
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.